Breaks Categories: Stock Spotlights

ThursdayFeb 15, 2018 3:10 pm

PsychedelicNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Utilizes Oral Digestion Technology to Expand Product Line

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) recently announced its entry into a licensing agreement with Cannfections Group Inc. The agreement offers Lexaria the ability to provide commercial clients with high quality chocolate edibles using its proprietary DehydraTECH™ oral digestion technology. An article discussing the company reads: “Lexaria has developed various products for demonstration, testing and sales, showing wide applicability. These non-psychoactive cannabinoid products have a high-absorption hemp oil formula, are an excellent source of omegas and essential fatty acids and are engineered for physiological performance and recovery. APIs within Lexaria’s products have been shown to reduce anxiety and stress while…

Continue Reading

MondayJan 29, 2018 11:38 am

PsychedelicNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Sees Potential to Lower Medication Doses Using Advanced Drug Delivery

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) has developed DehydraTECH™, a drug delivery platform that can be applied to various ingestible products such as foods, beverages, oral suspensions, tablets, capsules and more. An article discussing the company’s innovative drug delivery technology reads: “Lexaria’s DehydraTECH™ oral digestion technology is a ‘back office’ process that allows non-psychoactive cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and nicotine to be absorbed at much higher rates. The company has been working with the National Research Council of Canada (“NRC”), an agency of the Canadian federal government, to explore the effects of its technology. Lexaria’s superior delivery system…

Continue Reading

TuesdayJan 02, 2018 11:33 am

PsychedelicNewsBreaks – India Globalization Capital, Inc.’s (NYSE: IGC) Cannabis-based Eating Disorder Treatment Anticipated for PCT Filing in February

India Globalization Capital (NYSE American: IGC), a developer of cannabis-based therapies to treat a variety of life-altering conditions, has recently developed IGC-506 for the treatment of multiple types of eating disorders in humans, as well as animals in the veterinary market. The company expects to file a Patent Cooperation Treaty (“PCT”) application by February 28, 2018. PCT is an international patent filing effective in numerous foreign countries. An article discussing this reads: “IGC-506 is a combination therapy drug, developed from cannabis-extracts and other compounds, designed to treat multiple types of eating disorders. Cannabinoids are chemical compounds that exert a range…

Continue Reading

FridayDec 08, 2017 12:42 pm

PsychedelicNewsBreaks – Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) DehydraTech™ Shines in Vegas Lights

Lexaria Bioscience (CSE: LXX) (OTCQB: LXRP) attracted a lot of attention in Las Vegas at this year’s Marijuana Business Conference & Expo due to increased awareness about potential health benefits of cannabinoids and an increased demand for improved CBD-based edibles. A recent article highlights keen interest in Lexaria’s patented DehydraTECH™ delivery technology, stating, “Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids,…

Continue Reading

MondayNov 20, 2017 12:54 pm

PsychedelicNewsBreaks – Skinvisible Pharmaceuticals, Inc. (SKVI) Could Have the Solution to the Flu Epidemic

Skinvisible Pharmaceuticals (OTCQB: SKVI) is a topical and transdermal product development company with a proprietary drug delivery system, Invisicare, that improves how ingredients are delivered to and through the skin including the medicinal components of marijuana; specifically, CBD (cannabidiol) and the psychoactive marijuana ingredient THC (tetrahydrocannabinol). The key to Skinvisible's patented technology and trademarked Invisicare family of polymer delivery vehicles is its formula and process for combining hydrophilic and hydrophobic polymers into stable complexes in water emulsions. Applications of this novel technology are discussed in a recent article that says in part, “H7N9 (a type of avian influenza virus) could…

Continue Reading

ThursdayOct 12, 2017 9:30 am

PsychedelicNewsBreaks – Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) is Frontrunner in the Delivery of Non-Psychoactive Cannabinoids

Lexaria Biosciences Corp. (CSE: LXX) (OTCQB: LXRP), a biosciences company that has developed delivery technologies to improve absorption of bioactive compounds, has enhanced the ability of cannabinoid-products companies to deliver active ingredients to the body with its patent-protected technology. This technology is already being applied to the use of non-psychoactive cannabinoids, yielding a high-absorption hemp oil formula that is a source of omega and fatty acids, and patents are pending for tetrahydrocannabinol (THC) and other psychoactive cannabinoids along with nicotine and nonsteroidal anti-inflammatory drugs. An article discussing this reads: “The patent awarded to LXRP for the delivery of all non-psychoactive…

Continue Reading

FridaySep 15, 2017 1:58 pm

PsychedelicNewsBreaks – University of British Columbia to Conduct Clinical Study of Lexaria Bioscience Corp.’s (CSE: LXX) (OTCQB: LXRP) Game-Changing Oral CBD Product

While cannabidiol and other marijuana-derived substances are traditionally smoked, this can cause damage to the lungs, and edible cannabis products have their drawbacks, too—typically being filled with sugars or other sweeteners to mask the unpleasant flavor associated with cannabis compounds. With its pioneering TurboCBD™ product, however, Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) has revolutionized oral CBD intake, having engineered the product to enhance absorption through the intestinal tract without active compounds being destroyed by stomach acid or broken down by the liver, and this revolutionary product also masks the unpleasant flavor of cannabis compounds. An article further discussing this…

Continue Reading

FridayJul 28, 2017 12:12 pm

PsychedelicNewsBreaks – Algae Dynamics Corp. (ADYNF) Developing Potential Breakthrough Fortified Formulas to Boost Human Endocannabinoid System

As debates continue over the legalization of marijuana, many individuals who have never touched plant-derived cannabinoids (phytocannabinoids) do not realize that their bodies naturally produce endocannabinoids, which play an essential mediating role in various human physiologic systems. Recent studies have shown that the production of endocannabinoids is boosted by fatty acids, and Algae Dynamics (OTCQB: ADYNF) has begun developing fortified formulas of omega-3s and cannabis oil that could potentially boost the function of the human body’s endocannabinoid system. “The products under development by Algae Dynamics promise to pack a powerful therapeutic punch, combining the virtues of omega-3s and cannabinoids. Algae…

Continue Reading

MondayJul 17, 2017 2:55 pm

PsychedelicNewsBreaks – Algae Dynamics Corp. (ADYNF) is Revolutionizing Plant-Based Therapeutics for a Range of Ailments

Algae Dynamics Corp. (OTC: ADYNF) has developed a unique strategy of producing a variety of products that combine the health benefits of both algae and cannabis oils. The synergistic effects of the two plant-based remedies hold tremendous promise, and the ability to sell and cross market the products to health conscious consumers gives the company real competitive advantages. A recent PNW article highlights the company’s progress in this innovative endeavor and notes key partnerships established to achieve its corporate goals: “With an ongoing commitment to science, Algae Dynamics has engaged two Canadian universities to perform research and product development into…

Continue Reading

WednesdayJun 28, 2017 12:12 pm

PsychedelicNewsBreaks – Algae Dynamics Corp. (ADYNF) Targets Nutraceutical Market Leveraging Health and Efficacy Effects of Algae-Cannabis Oils

The nutraceutical industry boasts a diversified playing field, and Canada-based Algae Dynamics Corp. (OTCQB: ADYNF) is taking a unique approach to this burgeoning market, focusing on the development of proprietary research and products that combine the health benefits of botanical oils derived from cannabis and algae. “The original core of the company’s product development strategy was the extraction of Omega-3 fatty acids from certain strains of algae with high concentrations of DHA to create various nutraceutical products. As a result of the many demonstrated health benefits of other botanical oils, most notably cannabis oil, Algae Dynamics developed a strategy aimed…

Continue Reading